

# Benjamin Bonavida

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/284215/publications.pdf>

Version: 2024-02-01

197  
papers

8,098  
citations

<sup>31976</sup>  
53  
h-index

<sup>54911</sup>  
84  
g-index

198  
all docs

198  
docs citations

198  
times ranked

8110  
citing authors

#	ARTICLE	IF	CITATIONS
1	Computational Analyses of YY1 and Its Target RKIP Reveal Their Diagnostic and Prognostic Roles in Lung Cancer. <i>Cancers</i> , 2022, 14, 922.	3.7	5
2	The role of YY1 in the pathogenesis of rheumatoid arthritis: A tale of cytokines, ncRNAs, and aberrant fibroblast-like synoviocytes (FLSs). , 2021, , 311-335.		0
3	The role of YY1 in drug resistant cancer: Involvement of the YY1/PTEN/PP2A/H2Ax/Rad51 axis. , 2021, , 225-242.		0
4	Regulation of NKG2D by RKIP: Implications on NK-mediated cytotoxicity and cytokine production. , 2021, , 233-265.		1
5	YY1 expression and PD-1 regulation in CD8 T lymphocytes. , 2021, , 289-309.		1
6	Defective Natural Killer Cells in Melanoma: Role of NKG2D in Pathogenesis and Immunotherapy. <i>Critical Reviews in Immunology</i> , 2021, 41, 45-76.	0.5	2
7	RKIP: A Pivotal Gene Product in the Pathogenesis of Cancer. <i>Cancers</i> , 2021, 13, 2488.	3.7	3
8	YY1 Silencing Induces 5-Fluorouracil-Resistance and BCL2L15 Downregulation in Colorectal Cancer Cells: Diagnostic and Prognostic Relevance. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8481.	4.1	8
9	YY1 is involved in the pathogenesis and malignant properties of human triple-negative breast cancer (TNBC). , 2021, , 149-162.		1
10	Regulation of T Cells in Cancer by Nitric Oxide. <i>Cells</i> , 2021, 10, 2655.	4.1	25
11	Regulation of the c-myc Oncogene by the Circadian Clock and Oncogenesis. <i>Critical Reviews in Oncogenesis</i> , 2021, 26, 55-66.	0.4	1
12	Cross Talk between the Circadian Clock Proteins and TP53 in Cancer and Therapeutic Significance. <i>Critical Reviews in Oncogenesis</i> , 2021, 26, 19-36.	0.4	2
13	Commentary: Photodynamic Therapy-Induced Oxidative Stress and the Circadian Rhythm. <i>Critical Reviews in Oncogenesis</i> , 2021, 26, 67-73.	0.4	0
14	RKIP Pleiotropic Activities in Cancer and Inflammatory Diseases: Role in Immunity. <i>Cancers</i> , 2021, 13, 6247.	3.7	5
15	Role of the Transcription Factor Yin Yang 1 and Its Selectively Identified Target Survivin in High-Grade B-Cells Non-Hodgkin Lymphomas: Potential Diagnostic and Therapeutic Targets. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6446.	4.1	7
16	Sensitizing activities of nitric oxide donors for cancer resistance to anticancer therapeutic drugs. <i>Biochemical Pharmacology</i> , 2020, 176, 113913.	4.4	29
17	Cell-mediated immune resistance in cancer. , 2020, 3, 232-251.		9
18	Cross-Talk Cell Signaling between Anti-CD20 Antibodies and Nitric Oxide Donors. <i>Critical Reviews in Oncogenesis</i> , 2020, 25, 291-300.	0.4	0

#	ARTICLE	IF	CITATIONS
19	Pleiotropic activities of RKIP in cancer: Role in survival, EMT, chemo-immuno-resistance, and autophagy. , 2020, , 47-75.		1
20	Reversal of Resistance to Anti-CD20 Antibody Therapies: Targeting Intracellular Resistant Factors. Critical Reviews in Oncogenesis, 2020, 25, 275-290.	0.4	1
21	Vivid Memories of Sercarz's Traineeship and Am Indebted to Him for My Professional Career. Critical Reviews in Immunology, 2020, 40, 347-352.	0.5	0
22	Identification of regulatory crosstalks between RKIP and BRCA1 tumor suppressors in healthy tissues and cancer (breast and ovarian): Therapeutic implications. , 2020, , 175-209.		1
23	Crosstalks between Yin-Yang 1 (YY1) and autophagy in cancer. , 2020, , 9-27.		0
24	Nitric Oxide-Mediated Enhancement and Reversal of Resistance of Anticancer Therapies. Antioxidants, 2019, 8, 407.	5.1	40
25	YY1 regulates cancer cell immune resistance by modulating PD-L1 expression. Drug Resistance Updates, 2019, 43, 10-28.	14.4	81
26	Involvement of Yin Yang 1 (YY1) Expression in T-Cell Subsets Differentiation and Their Functions: Implications in T Cell-Mediated Diseases. Critical Reviews in Immunology, 2019, 39, 491-510.	0.5	8
27	Identifying Crosstalk between Raf Kinase Inhibitor Protein and Systemic Lupus Erythematosus. Critical Reviews in Immunology, 2019, 39, 423-437.	0.5	0
28	Overexpression of YY1 Regulates the Resistance of Cancer Stem Cells: Targeting YY1. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 93-113.	0.1	0
29	RKIP: A Key Regulator in Tumor Metastasis Initiation and Resistance to Apoptosis: Therapeutic Targeting and Impact. Cancers, 2018, 10, 287.	3.7	53
30	A New Linkage between the Tumor Suppressor RKIP and Autophagy: Targeted Therapeutics. Critical Reviews in Oncogenesis, 2018, 23, 281-305.	0.4	15
31	Linking Autophagy and the Dysregulated NF $\kappa$ B/ SNAIL/YY1/RKIP/PTEN Loop in Cancer: Therapeutic Implications. Critical Reviews in Oncogenesis, 2018, 23, 307-320.	0.4	22
32	Exosomes derived from cancerous and non-cancerous cells regulate the anti-tumor response in the tumor microenvironment. Genes and Cancer, 2018, 9, 87-100.	1.9	76
33	Inverse correlation between the metastasis suppressor RKIP and the metastasis inducer YY1: Contrasting roles in the regulation of chemo/immuno-resistance in cancer. Drug Resistance Updates, 2017, 30, 28-38.	14.4	39
34	Overexpression of RKIP and its cross-talk with several regulatory gene products in multiple myeloma. Journal of Experimental and Clinical Cancer Research, 2017, 36, 62.	8.6	24
35	Crosstalks between Raf-kinase inhibitor protein and cancer stem cell transcription factors (Oct4,) Tj ETQq1 1 0.784314 rgBT /Overloc	1.8	28
36	Nitric Oxide Donors Sensitize Resistant Cancer Cells to Apoptosis Induced by Chemotherapy: Molecular Mechanisms of Sensitization. , 2017, , 15-34.		2

#	ARTICLE	IF	CITATIONS
37	Targeting the Overexpressed YY1 in Cancer Inhibits EMT and Metastasis. <i>Critical Reviews in Oncogenesis</i> , 2017, 22, 49-61.	0.4	36
38	Therapeutic YY1 Inhibitors in Cancer: ALL in ONE. <i>Critical Reviews in Oncogenesis</i> , 2017, 22, 37-47.	0.4	22
39	The Forgotten YY2 in Reported YY1 Expression Levels in Human Cancers. <i>Critical Reviews in Oncogenesis</i> , 2017, 22, 63-73.	0.4	8
40	Activation of Natural Killer Cells by Probiotics. <i>Forum on Immunopathological Diseases and Therapeutics</i> , 2016, 7, 41-55.	0.1	32
41	Yin Yang 1 is associated with cancer stem cell transcription factors (SOX2, OCT4, BMI1) and clinical implication. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 84.	8.6	126
42	Correlation between the overexpression of Yin Yang 1 and the expression levels of miRNAs in Burkitt's lymphoma: A computational study. <i>Oncology Letters</i> , 2016, 11, 1021-1025.	1.8	53
43	Yin Yang 1 (YY1) Acting Primarily As an Oncogene and Rarely As a Tumor Suppressor in Distinct Hematological Malignancies: Prognostic and Therapeutic Implications. <i>Blood</i> , 2016, 128, 5122-5122.	1.4	0
44	Special collection: Nitric oxide in cancer. <i>Redox Biology</i> , 2015, 6, 505-506.	9.0	4
45	Regulation Of Cell Death Apoptotic Pathways By Nitric Oxide In Cancer: Reversal Of Drug/Immune Resistance. <i>Redox Biology</i> , 2015, 5, 415.	9.0	8
46	P38 MAPK expression and activation predicts failure of response to CHOP in patients with Diffuse Large B-Cell Lymphoma. <i>BMC Cancer</i> , 2015, 15, 722.	2.6	28
47	Overcoming rituximab drug-resistance by the genetically engineered anti-CD20-hIFN- $\beta$ fusion protein: Direct cytotoxicity and synergy with chemotherapy. <i>International Journal of Oncology</i> , 2015, 47, 1735-1748.	3.3	16
48	Prognostic significance of YY1 protein expression and mRNA levels by bioinformatics analysis in human cancers: A therapeutic target. , 2015, 150, 149-168.		46
49	Repeated sub-optimal photodynamic treatments with pheophorbide a induce an epithelial mesenchymal transition in prostate cancer cells via nitric oxide. <i>Nitric Oxide - Biology and Chemistry</i> , 2015, 45, 43-53.	2.7	36
50	Pivotal Role of Nitric Oxide in Chemo and Immuno Sensitization of Resistant Tumor Cells to Apoptosis. , 2015, , 179-201.		0
51	Dual roles of nitric oxide in the regulation of tumor cell response and resistance to photodynamic therapy. <i>Redox Biology</i> , 2015, 6, 311-317.	9.0	65
52	Nitric oxide-mediated sensitization of resistant tumor cells to apoptosis by chemo-immunotherapeutics. <i>Redox Biology</i> , 2015, 6, 486-494.	9.0	104
53	Sensitization of Immune-Resistant Tumor Cells to CTL-Mediated Apoptosis via Interference at the Dysregulated NF- $\kappa$ B/Snail/YY1/PI3K/RKIP/PTEN Resistant Loop. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2015, , 177-208.	0.1	0
54	KLF4 and YY1 Are Resistant Factors in NHL and Potential Therapeutic Targets: The New Resistant NF- $\kappa$ B/YY1/KLF4/BclxL/Mcl-1 Axis. <i>Blood</i> , 2015, 126, 1466-1466.	1.4	1

#	ARTICLE	IF	CITATIONS
55	NK Cell Phenotypic and Functional Heterogeneities and Molecular Mechanisms of Cytotoxicity. <i>Critical Reviews in Oncogenesis</i> , 2014, 19, 21-45.	0.4	6
56	Death receptor 5 expression is inversely correlated with prostate cancer progression. <i>Molecular Medicine Reports</i> , 2014, 10, 2279-2286.	2.4	13
57	Postulated Mechanisms of Resistance of B-Cell Non-Hodgkin Lymphoma to Rituximab Treatment Regimens: Strategies to Overcome Resistance. <i>Seminars in Oncology</i> , 2014, 41, 667-677.	2.2	43
58	Central role of Snail1 in the regulation of EMT and resistance in cancer: a target for therapeutic intervention. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014, 33, 62.	8.6	345
59	Overexpression of Yin Yang 1 in bone marrow-derived human multiple myeloma and its clinical significance. <i>International Journal of Oncology</i> , 2014, 45, 1184-1192.	3.3	26
60	Anti-Myeloma Activity by the Combination of the JAK2 Inhibitor Ruxolitinib with Lenalidomide and Corticosteroids. <i>Blood</i> , 2014, 124, 2114-2114.	1.4	7
61	Increased M2 Macrophages in Multiple Myeloma Patients with Progressive Disease and Down-Regulated Polarization with the JAK2 Inhibitor Ruxolitinib. <i>Blood</i> , 2014, 124, 4106-4106.	1.4	7
62	Raf Kinase Inhibitor Protein (RKIP) Blocks Signal Transducer and Activator of Transcription 3 (STAT3) Activation in Breast and Prostate Cancer. <i>PLoS ONE</i> , 2014, 9, e92478.	2.5	53
63	RKIP-Mediated Chemo-Immunosensitization of Resistant Cancer Cells via Disruption of the NF- $\kappa$ B/Snail/YY1/RKIP Resistance-Driver Loop. <i>Critical Reviews in Oncogenesis</i> , 2014, 19, 431-445.	0.4	31
64	Role of YY1 in the pathogenesis of prostate cancer and correlation with bioinformatic data sets of gene expression. <i>Genes and Cancer</i> , 2014, 5, 71-83.	1.9	29
65	Trop2 and its overexpression in cancers: regulation and clinical/ therapeutic implications. <i>Genes and Cancer</i> , 2014, 6, 84-105.	1.9	200
66	Nitric oxide-mediated activity in anti-cancer photodynamic therapy. <i>Nitric Oxide - Biology and Chemistry</i> , 2013, 30, 26-35.	2.7	75
67	Contribution of either YY1 or BclXL-induced inhibition by the NO-donor DETANONOate in the reversal of drug resistance, both in vitro and in vivo. YY1 and BclXL are overexpressed in prostate cancer. <i>Nitric Oxide - Biology and Chemistry</i> , 2013, 29, 17-24.	2.7	57
68	Galiximab (anti-CD80)-induced growth inhibition and prolongation of survival in vivo of B-NHL tumor xenografts and potentiation by the combination with fludarabine. <i>International Journal of Oncology</i> , 2013, 43, 670-676.	3.3	9
69	Abstract 5450: High expression of KrÄ¼ppel-Like Factor 4 (KLF4) and its regulation by Yin Yang 1 (YY1) in non-Hodgkin's B-cell lymphomas: clinical implication.. , 2013, , .		2
70	Roles Each of Snail, Yin Yang 1, and RKIP in the Regulation of Tumor Cells Chemo-Immuno-Resistance to Apoptosis. <i>Forum on Immunopathological Diseases and Therapeutics</i> , 2013, 4, 79-92.	0.1	16
71	Tumor Resistance to Antibody-Mediated Immunotherapy and Reversal of Resistance: Rituximab as Prototype. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2013, , 93-124.	0.1	0
72	Galiximab Signals B-NHL Cells and Inhibits the Activities of NF- $\kappa$ B-Induced YY1- and Snail-Resistant Factors: Mechanism of Sensitization to Apoptosis by Chemoimmunotherapeutic Drugs. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 572-581.	4.1	20

#	ARTICLE	IF	CITATIONS
73	Inhibition of Epithelial-to-Mesenchymal Transition (EMT) in Cancer by Nitric Oxide: Pivotal Roles of Nitrosylation of NF- $\kappa$ B, YY1 and Snail. Forum on Immunopathological Diseases and Therapeutics, 2012, 3, 125-133.	0.1	24
74	A potential mechanism of rituximab-induced inhibition of tumor growth through its sensitization to tumor necrosis factor-related apoptosis-inducing ligand-expressing host cytotoxic cells. Leukemia and Lymphoma, 2011, 52, 108-121.	1.3	31
75	The anti-CD20 mAb LFB-R603 interrupts the dysregulated NF- $\kappa$ B/Snail/RKIP/PTEN resistance loop in B-NHL cells: Role in sensitization to TRAIL apoptosis. International Journal of Oncology, 2011, 38, 1683-94.	3.3	25
76	Dual role of NO donors in the reversal of tumor cell resistance and EMT: Downregulation of the NF- $\kappa$ B/Snail/YY1/RKIP circuitry. Nitric Oxide - Biology and Chemistry, 2011, 24, 1-7.	2.7	121
77	Development of Rituximab-Resistant B-NHL Clones: An In Vitro Model for Studying Tumor Resistance to Monoclonal Antibody-Mediated Immunotherapy. Methods in Molecular Biology, 2011, 731, 407-419.	0.9	3
78	Preface: Special Issue on Yin Yang 1 and Oncogenesis. Critical Reviews in Oncogenesis, 2011, 16, 141-142.	0.4	0
79	The Novel Role of Yin Yang 1 in the Regulation of Epithelial to Mesenchymal Transition in Cancer Via the Dysregulated NF- $\kappa$ B/Snail/YY1/RKIP/PTEN Circuitry. Critical Reviews in Oncogenesis, 2011, 16, 211-226.	0.4	75
80	Overexpression of Yin Yang 1 in the Pathogenesis of Human Hematopoietic Malignancies. Critical Reviews in Oncogenesis, 2011, 16, 261-267.	0.4	18
81	Expression of phosphorylated raf kinase inhibitor protein (pRKIP) is a predictor of lung cancer survival. BMC Cancer, 2011, 11, 259.	2.6	39
82	Mcl-1 and YY1 inhibition and induction of DR5 by the BH3-mimetic Obatoclax (GX15-070) contribute in the sensitization of B-NHL cells to TRAIL apoptosis. Cell Cycle, 2011, 10, 2792-2805.	2.6	45
83	Cytotoxic Activity of Anti-CD20-hIFN- $\gamma$ on Rituximab-Resistant B-NHL Clones and Synergy with Chemotherapy. Blood, 2011, 118, 3499-3499.	1.4	6
84	Dual Roles of Raf-1 Kinase Inhibitor Protein in the Regulation of Both Tumor Cell Resistance to Apoptotic Stimuli and Epithelial to Mesenchymal Transition. Forum on Immunopathological Diseases and Therapeutics, 2011, 2, 95-109.	0.1	1
85	Unique Pattern of Overexpression of Raf-1 Kinase Inhibitory Protein in Its Inactivated Phosphorylated Form in Human Multiple Myeloma. Forum on Immunopathological Diseases and Therapeutics, 2011, 2, 179-188.	0.1	14
86	Targeting the Over-Expressed Transcription Factor Yin-Yang 1 (YY1) Sensitizes Resistant Multiple Myeloma (MM) Cell Lines to Apoptosis by Bortezomib or Melphalan. Blood, 2011, 118, 3991-3991.	1.4	0
87	Unresponsiveness to CHOP Is Associated with Activation of the p38 MAPK Pathway in Patients with DLBCL. Blood, 2011, 118, 2647-2647.	1.4	0
88	Upregulation of KLF4 Expression in Pediatric B-NHL Lymphomas and Its Association with Low EFS and Poor Survival Following Treatment with Chemotherapy. Blood, 2011, 118, 5184-5184.	1.4	0
89	Autoantibodies Directed Against Moesin C471-577/N1-297 Are Novel and Specific Biomarkers of Immune Thrombocytopenic Purpura (ITP). Blood, 2011, 118, 3301-3301.	1.4	13
90	Novel Therapeutic Applications of Nitric Oxide in the Inhibition of Tumor Malignancy and Reversal of Resistance. , 2010, , 813-830.		2

#	ARTICLE	IF	CITATIONS
91	The Role of B-RAF Mutations in Melanoma and the Induction of EMT via Dysregulation of the NF- $\kappa$ B/Snail/RKIP/PTEN Circuit. <i>Genes and Cancer</i> , 2010, 1, 409-420.	1.9	127
92	Mechanisms of nitric oxide-mediated inhibition of EMT in cancer. <i>Cell Cycle</i> , 2010, 9, 4931-4940.	2.6	97
93	Nitric Oxide Donors Are a New Class of Anti-cancer Therapeutics for the Reversal of Resistance and Inhibition of Metastasis. , 2010, , 459-477.		9
94	Viral Infection and Cancer: The NF- $\kappa$ B/Snail/RKIP Loop Regulates Target Cell Sensitivity to Apoptosis by Cytotoxic Lymphocytes. <i>Critical Reviews in Immunology</i> , 2010, 30, 31-46.	0.5	29
95	DETANONOate Is a Potent Chemo Radio-Sensitizing Agent in Colon and Colorectal Cancers as Assessed in In Vitro and In Vivo Established Tumor Xenografts. <i>Forum on Immunopathological Diseases and Therapeutics</i> , 2010, 1, 281-295.	0.1	3
96	Nitric Oxide Inhibits Tumor Cell Metastasis via Dysregulation of the NF- $\kappa$ B/Snail/RKIP Loop. , 2010, , 209-233.		0
97	Reversal of Drug/TRAIL-Resistant B-NHL Cells to Apoptosis by the Combination of Rituximab (anti-CD20) and Either Mapatumumab or Lexatumumab. <i>Blood</i> , 2010, 116, 4931-4931.	1.4	0
98	Photodynamic Therapy (PDT)-Mediated Inhibition of the Transcription Factor Yin Yang 1 (YY1) That Regulates Resistance In Lymphoma. <i>Blood</i> , 2010, 116, 5113-5113.	1.4	0
99	Dysregulation of the cell survival/anti-apoptotic NF- $\kappa$ B pathway by the novel humanized BM-ca anti-CD20 mAb: Implication in chemosensitization. <i>International Journal of Oncology</i> , 2009, 35, 1289-96.	3.3	15
100	The Activated NF- $\kappa$ B-Snail-RKIP Circuitry in Cancer Regulates Both the Metastatic Cascade and Resistance to Apoptosis by Cytotoxic Drugs. <i>Critical Reviews in Immunology</i> , 2009, 29, 241-254.	0.5	116
101	BRAF and RKIP are significantly decreased in cutaneous squamous cell carcinoma. <i>Cell Cycle</i> , 2009, 8, 1402-1408.	2.6	46
102	Chemosensitization and Immunosenitization of Resistant Cancer Cells to Apoptosis and Inhibition of Metastasis by the Specific NF- $\kappa$ B Inhibitor DHMEQ. <i>Current Pharmaceutical Design</i> , 2009, 15, 792-808.	1.9	56
103	Rituximab-Mediated Cell Signaling and Chemo/Immuno-sensitization of Drug-Resistant B-NHL Is Independent of Its Fc Functions. <i>Clinical Cancer Research</i> , 2009, 15, 6582-6594.	7.0	59
104	Pivotal Roles of Snail Inhibition and RKIP Induction by the Proteasome Inhibitor NPI-0052 in Tumor Cell Chemoimmunosenitization. <i>Cancer Research</i> , 2009, 69, 8376-8385.	0.9	95
105	Nitric oxide sensitizes tumor cells to TRAIL-induced apoptosis via inhibition of the DR5 transcription repressor Yin Yang 1. <i>Nitric Oxide - Biology and Chemistry</i> , 2009, 20, 39-52.	2.7	81
106	In vitro and in vivo sensitization of SW620 metastatic colon cancer cells to CDDP-induced apoptosis by the nitric oxide donor DETANONOate: Involvement of AIF. <i>Nitric Oxide - Biology and Chemistry</i> , 2009, 20, 182-194.	2.7	49
107	YY1 Over-Expression in Human Brain Gliomas and Meningiomas Correlates with TGF- $\beta$ 1, IGF-1 and FGF-2 mRNA Levels. <i>Cancer Investigation</i> , 2009, 27, 184-192.	1.3	50
108	2-Methoxyestradiol (2-ME) reduces the airway inflammation and remodeling in an experimental mouse model. <i>Clinical Immunology</i> , 2008, 129, 313-324.	3.2	39

#	ARTICLE	IF	CITATIONS
109	The NF- $\kappa$ B inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs. <i>Leukemia and Lymphoma</i> , 2008, 49, 1982-1994.	1.3	25
110	Novel therapeutic applications of nitric oxide donors in cancer: Roles in chemo- and immunosensitization to apoptosis and inhibition of metastases. <i>Nitric Oxide - Biology and Chemistry</i> , 2008, 19, 152-157.	2.7	142
111	Inhibition of Yin Yang 1-Dependent Repressor Activity of DR5 Transcription and Expression by the Novel Proteasome Inhibitor NPI-0052 Contributes to its TRAIL-Enhanced Apoptosis in Cancer Cells. <i>Journal of Immunology</i> , 2008, 180, 6199-6210.	0.8	78
112	NF- $\kappa$ B in the pathogenesis and treatment of multiple myeloma. <i>Current Opinion in Hematology</i> , 2008, 15, 391-399.	2.5	91
113	Prognostic Significance of Both the Cytoplasmic and Nuclear Overexpression of Yin-Yang 1 (YY1) among Patients with Multiple Myeloma (MM). <i>Blood</i> , 2008, 112, 2730-2730.	1.4	6
114	Tumor Cell Resistance to Apoptosis by Infiltrating Cytotoxic Lymphocytes. , 2008, , 121-137.		0
115	Nitric Oxide-Induced Immunosensitization to Apoptosis by Fas-L and TRAIL. , 2008, , 203-210.		1
116	Chemo-Immunosensitization of Resistant B-NHL as a Result of Rituximab (anti-CD20 mAb)-Mediated Inhibition of Cell Survival Signaling Pathways. , 2008, , 29-39.		1
117	Nitric oxide donors: novel cancer therapeutics (review). <i>International Journal of Oncology</i> , 2008, 33, 909-27.	3.3	57
118	Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 1387-1399.	4.1	144
119	Regulation of Tumor Cell Sensitivity to TRAIL-Induced Apoptosis by the Metastatic Suppressor Raf Kinase Inhibitor Protein via Yin Yang 1 Inhibition and Death Receptor 5 Up-Regulation. <i>Journal of Immunology</i> , 2007, 179, 5441-5453.	0.8	101
120	Development of Rituximab-Resistant Lymphoma Clones with Altered Cell Signaling and Cross-Resistance to Chemotherapy. <i>Cancer Research</i> , 2007, 67, 1270-1281.	0.9	154
121	Expression of X-Linked Inhibitor of Apoptosis Protein Is a Strong Predictor of Human Prostate Cancer Recurrence. <i>Clinical Cancer Research</i> , 2007, 13, 6056-6063.	7.0	74
122	The NO TRAIL to YES TRAIL in cancer therapy (Review). <i>International Journal of Oncology</i> , 2007, 31, 685.	3.3	11
123	Reversal of resistance to cytotoxic cancer therapies: DHMEQ as a chemo-sensitizing and immuno-sensitizing agent. <i>Drug Resistance Updates</i> , 2007, 10, 1-12.	14.4	28
124	Modification of Gene Products Involved in Resistance to Apoptosis in Metastatic Colon Cancer Cells: Roles of Fas, Apaf-1, NF- $\kappa$ B, IAPs, Smac/DIABLO, and AIF. <i>Journal of Surgical Research</i> , 2007, 142, 184-194.	1.6	83
125	Reversal of Tumor Resistance to Apoptotic Stimuli by Alteration of Membrane Fluidity: Therapeutic Implications. <i>Advances in Cancer Research</i> , 2007, 98, 149-190.	5.0	71
126	Cytotoxicity of Genetically Engineered Fusion Protein with CD154 Peptide Mimetic (OmpC-CD154p) on B-NHL Cell Lines.. <i>Blood</i> , 2007, 110, 4525-4525.	1.4	0



#	ARTICLE	IF	CITATIONS
127	Rituximab Sensitizes TRAIL-Resistant B-NHL Lines to Apoptosis by Both TRAIL and Fully Humanized Antibodies Targeting TRAIL-R1 (Mapatumumab) and TRAIL-R2 (Lexatumumab).. Blood, 2007, 110, 2350-2350.	1.4	1
128	The NO TRAIL to YES TRAIL in cancer therapy (review). International Journal of Oncology, 2007, 31, 685-91.	3.3	23
129	Therapeutic potential of nitric oxide in cancer. Drug Resistance Updates, 2006, 9, 157-173.	14.4	106
130	What signals are generated by anti-CD20 antibody therapy?. Current Hematologic Malignancy Reports, 2006, 1, 205-213.	2.3	8
131	Involvement of the TNF- $\alpha$ autocrine/paracrine loop, via NF- $\kappa$ B and YY1, in the regulation of tumor cell resistance to Fas-induced apoptosis. Clinical Immunology, 2006, 120, 297-309.	3.2	69
132	Nitric Oxide Sensitizes B-NHL Cells to TRAIL-Mediated Apoptosis through Induction of RKIP, Inhibition of YY1 and Upregulation of DR5.. Blood, 2006, 108, 4604-4604.	1.4	1
133	Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20) Tj ETQq1 1 0.784314 rgBT /Overloc Oncogene, 2005, 24, 2121-2143.	5.9	258
134	Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis. Oncogene, 2005, 24, 8114-8127.	5.9	97
135	Rituximab-Induced Inhibition of YY1 and Bcl-xL Expression in Ramos Non-Hodgkin's Lymphoma Cell Line via Inhibition of NF- $\kappa$ B Activity: Role of YY1 and Bcl-xL in Fas Resistance and Chemoresistance, Respectively. Journal of Immunology, 2005, 175, 2174-2183.	0.8	126
136	Inhibition of the transcription factor Yin Yang 1 activity by S-nitrosation. Biochemical and Biophysical Research Communications, 2005, 336, 692-701.	2.1	96
137	Rituximab-mediated chemosensitization of AIDS and non-AIDS non-Hodgkin's Lymphoma. Drug Resistance Updates, 2005, 8, 27-41.	14.4	9
138	Sensitization of Rituximab-Sensitive and Rituximab-Resistant B-NHL Cell Lines/Clones to TRAIL-Induced Apoptosis by Bortezomib and NF- $\kappa$ B Inhibitors.. Blood, 2005, 106, 1514-1514.	1.4	2
139	Chemosensitization of Drug-Resistant Ramos B-NHL to Drug-Induced Apoptosis: YY1 Expression Is Decreased in Response to Cytoskeletal-Interacting Drugs.. Blood, 2005, 106, 4806-4806.	1.4	0
140	Blocking Pleiotrophin Activity Inhibits Multiple Myeloma (MM) Cell Growth In Vitro and in a Severe Combined Immunodeficient (SCID)-hu Murine Model of Human MM.. Blood, 2005, 106, 114-114.	1.4	1
141	Circulating Tie2-Expressing Cells Are Increased in Multiple Myeloma Patients, Correlate with Serum Pleiotrophin Levels and May Develop from This Myeloma Angiogenic and Growth Factor.. Blood, 2005, 106, 2494-2494.	1.4	0
142	Analysis of YY1 and XIAP Expression, Proteins That Regulate Resistance, in AIDS-NHL Tissue Arrays.. Blood, 2005, 106, 1933-1933.	1.4	0
143	Overexpression and Preferential Nuclear Translocation of the Transcription Factor Yin Yang 1 (YY1) in Human Bone Marrow-Derived Multiple Myeloma.. Blood, 2005, 106, 3394-3394.	1.4	0
144	Reversal of Rituximab-Resistant AIDS-B-NHL Clone to Chemotherapeutic Drug-Induced Apoptosis by Bortezomib and DHMEQ.. Blood, 2005, 106, 1516-1516.	1.4	1

#	ARTICLE	IF	CITATIONS
145	Serum Pleiotrophin Is a New Multiple Myeloma Tumor Marker That Also Predicts Clinical Status.. Blood, 2005, 106, 3417-3417.	1.4	0
146	Differential Presence of Truncated Forms of Transcription Factor Yin Yang 1 (YY1) in Bone Marrow of Multiple Myeloma Patients.. Blood, 2005, 106, 5083-5083.	1.4	0
147	Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor- $\kappa$ B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Research, 2005, 65, 264-76.	0.9	134
148	Expression of transcription factor Yin Yang 1 in prostate cancer. International Journal of Oncology, 2005, 27, 131-41.	3.3	68
149	Inhibition of the Raf $\rightarrow$ MEK1/2 $\rightarrow$ ERK1/2 Signaling Pathway, Bcl-xL Down-Regulation, and Chemosensitization of Non-Hodgkin's Lymphoma B Cells by Rituximab. Cancer Research, 2004, 64, 7117-7126.	0.9	188
150	Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: Pivotal role of p38 MAPK in drug resistance. Oncogene, 2004, 23, 3530-3540.	5.9	131
151	Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF- $\kappa$ B and inhibition of Bcl-xL expression. Oncogene, 2004, 23, 4993-5003.	5.9	166
152	Ascorbic Acid Overcomes Drug Resistance in Myeloma and Significantly Increases the Anti-Myeloma Effects of both Arsenic Trioxide and Melphalan In Vitro and in Vivo.. Blood, 2004, 104, 2470-2470.	1.4	3
153	Cellular and Molecular Characterization of Rituximab-Resistant CD20+ NHL Ramos (Ramos RR1) and Daudi (Daudi RR1) Clones: Development of Cross-Resistance to Cytotoxic Stimuli.. Blood, 2004, 104, 3410-3410.	1.4	9
154	Sensitization of Rituximab-Resistant Ramos RR1 and Daudi RR1 Clones to Various Chemotherapeutic Drugs by a Novel Nuclear Factor- $\kappa$ B Activation Inhibitor.. Blood, 2004, 104, 83-83.	1.4	10
155	Arsenic Trioxide Shows Synergistic Anti-Myeloma Effects When Combined with Bortezomib and Melphalan In Vitro and Helps Overcome Resistance of Multiple Myeloma Cells to These Treatments in Vivo.. Blood, 2004, 104, 2467-2467.	1.4	3
156	Pleiotrophin Is Highly Expressed by Myeloma Cells, Elevated in the Serum of Myeloma Patients, and Is a New Autocrine Growth Factor for This B Cell Malignancy.. Blood, 2004, 104, 3349-3349.	1.4	6
157	Inhibition of Multiple Myeloma Cell Proliferation and Increase of Apoptosis through Regulation of the NF- $\kappa$ B and JNK Pathways by Silencing TRAF6 C-Domain mRNA.. Blood, 2004, 104, 3355-3355.	1.4	4
158	Rituximab-Mediated Inhibition of the Transcription Repressor Yin-Yang 1 (YY1) in NHL B Cell Lines: Upregulation of Fas Expression and Sensitization to Fas-Induced Apoptosis.. Blood, 2004, 104, 287-287.	1.4	2
159	Pleiotrophin Alone Induces Transdifferentiation of Human Monocytes and Bone Marrow Stem Cells into Endothelial Cells.. Blood, 2004, 104, 1472-1472.	1.4	0
160	Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis. Molecular Cancer Therapeutics, 2004, 3, 71-84.	4.1	81
161	Mechanism of activation of human peripheral blood NK cells at the single cell level by Echinacea water soluble extracts: recruitment of lymphocyte $\rightarrow$ target conjugates and killer cells and activation of programming for lysis. International Immunopharmacology, 2003, 3, 811-824.	3.8	19
162	Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clinical Cancer Research, 2003, 9, 316-26.	7.0	195

#	ARTICLE	IF	CITATIONS
163	Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis. <i>Molecular Cancer Therapeutics</i> , 2003, 2, 1183-93.	4.1	70
164	Rituximab-Mediated Sensitization of B-Non-Hodgkin's Lymphoma (NHL) to Cytotoxicity Induced by Paclitaxel, Gemcitabine, and Vinorelbine. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2002, 17, 621-630.	1.0	41
165	A new challenge for successful immunotherapy by tumors that are resistant to apoptosis: Two complementary signals to overcome cross-resistance. <i>Advances in Cancer Research</i> , 2002, 85, 145-174.	5.0	50
166	Mechanism of Norepinephrine-Mediated Inhibition of Human NK Cytotoxic Functions: Inhibition of Cytokine Secretion, Target Binding, and Programming for Cytotoxicity. <i>Brain, Behavior, and Immunity</i> , 2002, 16, 227-246.	4.1	52
167	Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: Role of XIAP in resistance. <i>Prostate</i> , 2002, 53, 286-299.	2.3	92
168	Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma. <i>Clinical Cancer Research</i> , 2002, 8, 836-45.	7.0	66
169	X-linked inhibitor of apoptosis (XIAP) blocks Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: sensitization by overexpression of second mitochondria-derived activator of caspase/direct IAP-binding protein with low pl (Smac/DIABLO). <i>Molecular Cancer Therapeutics</i> , 2002, 1, 1053-9.	4.1	75
170	ENHANCED SENSITIVITY OF BLADDER CANCER CELLS TO TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND MEDIATED APOPTOSIS BY CISPLATIN AND CARBOPLATIN. <i>Journal of Urology</i> , 2001, 165, 263-270.	0.4	72
171	Actinomycin D and Gemcitabine Synergistically Sensitize Androgen-Independent Prostate Cancer Cells to Apo2L/TRAIL-Mediated Apoptosis. <i>Journal of Immunotherapy</i> , 2001, 24, 459-471.	2.4	53
172	Nitric Oxide Disrupts H2O2-dependent Activation of Nuclear Factor $\kappa$ B. <i>Journal of Biological Chemistry</i> , 2001, 276, 8918-8923.	3.4	65
173	Nitric Oxide Inhibits the Transcription Repressor Yin-Yang 1 Binding Activity at the Silencer Region of the Fas Promoter: A Pivotal Role for Nitric Oxide in the Up-Regulation of Fas Gene Expression in Human Tumor Cells. <i>Journal of Immunology</i> , 2001, 167, 75-81.	0.8	148
174	Nitric Oxide Sensitizes Ovarian Tumor Cells to Fas-Induced Apoptosis. <i>Gynecologic Oncology</i> , 1999, 73, 257-264.	1.4	100
175	Blocking signaling through the gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity. <i>Cancer</i> , 1999, 85, 134-144.	4.1	75
176	Sensitization of immunoresistant prostate carcinoma cell lines to Fas/Fas ligand-mediated killing by cytotoxic lymphocytes: Independence of de novo protein synthesis. , 1999, 41, 20-30.		24
177	Chimeric Anti-CD20 (IDEC-C2B8) Monoclonal Antibody Sensitizes a B Cell Lymphoma Cell Line to Cell Killing by Cytotoxic Drugs. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 1997, 12, 177-186.	1.0	350
178	Doxorubicin sensitizes human bladder carcinoma cells to Fas-mediated cytotoxicity. , 1997, 79, 1180-1189.		73
179	Differential secretion of TNF- $\alpha$ and IFN- $\gamma$ by human peripheral blood-derived NK subsets and association with functional maturation. <i>Journal of Clinical Immunology</i> , 1996, 16, 46-54.	3.8	46
180	Involvement of the mitochondrion respiratory chain in the synergy achieved by treatment of human ovarian carcinoma cell lines with both tumor necrosis factor- $\alpha$ and cis-diamminedichloroplatinum. <i>Cancer</i> , 1996, 77, 725-732.	4.1	33

#	ARTICLE	IF	CITATIONS
181	Interferon- $\gamma$ activates cytotoxic function but inhibits interleukin-2-mediated proliferation and tumor necrosis factor- $\gamma$ secretion by immature human natural killer cells. <i>Journal of Clinical Immunology</i> , 1995, 15, 35-44.	3.8	68
182	Lysis of uninfected HIV-1 gp120-coated peripheral blood-derived T lymphocytes by monocyte-mediated antibody-dependent cellular cytotoxicity. <i>FEMS Immunology and Medical Microbiology</i> , 1995, 10, 83-92.	2.7	10
183	Lysis of uninfected HIV-1 gp120-coated peripheral blood-derived T lymphocytes by monocyte-mediated antibody-dependent cellular cytotoxicity. <i>FEMS Immunology and Medical Microbiology</i> , 1995, 10, 83-91.	2.7	1
184	Platelet-activating factor and the cytokine network in inflammatory processes. <i>Clinical Reviews in Allergy</i> , 1995, 12, 381-395.	1.0	26
185	Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide. <i>Cancer</i> , 1994, 74, 2546-2554.	4.1	68
186	Overcoming TNF- $\alpha$ and Drug Resistance of Human Renal Cell Carcinoma Cells by Treatment with Pentoxifylline in Combination with TNF- $\alpha$ or Drugs: The Role of TNF- $\alpha$ mRNA Downregulation in Tumor Cell Sensitization. <i>Journal of Urology</i> , 1994, 151, 1697-1702.	0.4	23
187	Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide. , 1994, 74, 2546.		1
188	Overcoming cis-diamminedichloroplatinum (II) resistance of human ovarian tumor cells by combination treatment with cis-diamminedichloroplatinum (II) and tumor necrosis factor- $\alpha$ . <i>Cancer</i> , 1993, 72, 809-818.	4.1	36
189	Immunomodulatory effect of tumor necrosis factor. <i>Biotherapy (Dordrecht, Netherlands)</i> , 1991, 3, 127-133.	0.7	44
190	Cycloheximide-induced modulation of TNF-mediated cytotoxicity in sensitive and resistant ovarian tumor cells. <i>Cancer Chemotherapy and Pharmacology</i> , 1990, 26, 1-8.	2.3	28
191	Cytotoxic and cytostatic effects of the streptococcal preparation OK-432 and its subcellular fractions on human ovarian tumor cells. <i>Cancer</i> , 1989, 64, 434-441.	4.1	17
192	A spontaneous sarcoma dependent on host tumor-specific immune lymphocytes. <i>BioEssays</i> , 1989, 11, 181-185.	2.5	2
193	Role of natural killer cytotoxic factors in the mechanism of target-cell killing by natural killer cells. <i>Journal of Clinical Immunology</i> , 1986, 6, 1-8.	3.8	46
194	Molecular Interactions in T-Cell-Mediated Cytotoxicity. <i>Immunological Reviews</i> , 1983, 72, 119-141.	6.0	22
195	Direct estimation of frequency of cytotoxic T lymphocytes by a modified plaque assay. <i>Nature</i> , 1976, 263, 769-771.	27.8	15
196	Transplantation of allogeneic lymphoid cells specifically depleted of graft versus host reactive cells. <i>Nature</i> , 1974, 249, 658-659.	27.8	20
197	Natural Killer Cells in HIV Infection and Role in the Pathogenesis of AIDS. , 0, , 183-205.		0